In the latest session, Quoin Pharmaceuticals Ltd ADR (NASDAQ: QNRX) closed at $1.50 down -48.28% from its previous closing price of $2.90. In other words, the price has decreased by -$1.4000 from its previous closing price. On the day, 3930980 shares were traded. QNRX stock price reached its highest trading level at $1.7400 during the session, while it also had its lowest trading level at $1.4402.
Ratios:
For a deeper understanding of Quoin Pharmaceuticals Ltd ADR’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.09 and its Current Ratio is at 3.09. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, QNRX now has a Market Capitalization of 1.47M and an Enterprise Value of 2.36M.
Stock Price History:
Over the past 52 weeks, QNRX has reached a high of $12.00, while it has fallen to a 52-week low of $2.25. The 50-Day Moving Average of the stock is 3.7081, while the 200-Day Moving Average is calculated to be 4.9450.
Shares Statistics:
For the past three months, QNRX has traded an average of 454.92K shares per day and 2.61M over the past ten days. Shares short for QNRX as of Feb 15, 2024 were 2.66k with a Short Ratio of 0.01, compared to 793 on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 0.27% and a Short% of Float of 0.27%.
Earnings Estimates
There are 2 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$2.31 for the current quarter, with a high estimate of -$2.26 and a low estimate of -$2.37, while EPS last year was -$4.92. The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between -$9.09 and -$9.85 for the fiscal current year, implying an average EPS of -$9.47. EPS for the following year is -$6.87, with 2 analysts recommending between -$4.39 and -$9.36.
